References
- Bray F, Ferlay J, Soerjomataram I, et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6): 394–424. 2018.
- European Commission. Estimates of cancer incidence and mortality in 2018, for all countries. Retrieved from ECIS - European Cancer Information System 14 November, 2019. [cited 2019 Nov 14]. Available from: https://ecis.jrc.ec.europa.eu/
- International Agency for Research on Cancer- Global Cancer Observatory. Estimates of stomach cancer incidence and mortality in 2018. [ cited 2019 November 14]. Available from: https://gco.iarc.fr/
- Chivu-Economescu M, Matei L, Necula LG, et al. New therapeutic options opened by the molecular classification of gastric cancer. World J Gastroenterol. 2018 May 14;24(18):1942–1961.
- Zheng Y, Zhu X-Q, Ren X-G. Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2017 Jun;96(24):e6884.
- Smyth E, Verheij M, Allum W, et al., Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27(suppl 5): 27. 2016.
- European Medicines Agency (EMA). Lonsurf : EPAR - Product information. ( Last updated 08 October 2019). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf#authorisation-details-section.
- Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1437–1448.
- Gourzoulidis G, Kourlaba G, Kakisis J, et al. Cost–effectiveness analysis of rivaroxaban for treatment of deep vein thrombosis and pulmonary embolism in Greece. Clin Drug Investig. 2017;37(9):833–844.
- Gourzoulidis G, Tzanetakos C, Ioannidis I, et al. Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece. Clin Drug Investig. 2018 May;38(5):417–426.
- National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. [ cited 2020 February 1]. Available from: https://www.nice.org.uk/process/pmg9/chapter/involvement-and-participation.
- Jou E, Rajdev L. Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol. 2016 May 28;22(20):4812–4823.
- Fanotto V, Uccello M, Pecora I, et al. Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy. The Oncologist. 2017 Dec;22(12):1463–1469.
- Latimer N NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. Sheffield: Report by the Decision Support Unit. 2011.
- National Institute for Health and Care Excellence (NICE). Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy: technology appraisal guidance [TA378]: committee Papers. (Updated: 15 September 2015); [ cited 2018 July 13]. Available from: https://www.nice.org.uk/guidance/ta378/history.
- Kontodimopoulos N, Aletras VH, Paliouras D, et al. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health. 2009 Nov-Dec;12(8):1151–1157.
- National Institute for Health and Care Excellence (NICE). Evaluation report 2. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen: technology appraisal [TA316]. 2014 (Updated 28 January 2014); [ cited 2018 August 29]. Available from: https://www.nice.org.uk/guidance/ta316/history.
- Greek Ministry of Health. Drug price bulletin. Available from. Accessed. 2020;1(May):2020. https://wwwmohgovgr/articles/times-farmakwn/deltia-timwn/6924-epikairopoihmeno-deltio-timwn-farmakwn-anthrwpinhs-xrhshs-me-enswmatwsh-deltioy-timwn-newn-farmakwn-2019-dioikhtikwn-metabolwn-allaghs-fpa-kai-anaprosarmoghs-timwn-gia-logoys-dhmosias-ygeias9
- National Organisation for Healthcare Services Provision. Official website of EOPYY. 2019. [cited 2020 May 25]. Available from: https://eopyyfiles.blob.core.windows.net/eopyysite/ServiceCategories/698a3227-5a43-4c19-b090-0d5e190ec81a.pdf.
- Gourzoulidis G, Maniadakis N, Petrakis D, et al. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece. J Comp Eff Res. 2019 Feb;8(3):133–142.
- STAT.) HSAE. Available from: https://www.statistics.gr/en/home/. [ cited 14 February 2020].
- Greek Ministry of Health. DRG code: Σ22Μ. Diagnostic Related Groups 2020 May 1. [cited 2020 May 25]. Available from: http://kenicd.e-healthnet.gr/%CE%A0%CF%81%CE%BF%CE%B2%CE%BF%CE%BB%CE%B7.aspx
- Greek Ministry of Health. DRG code: Α35X. Diagnostic Related Groups 2020 May 1. Available from: http://kenicd.e-healthnet.gr/KEN%CE%91%CE%BD%CE%B1%CE%BB%CF%85%CF%84%CE%B9%CE%BA%CE%AC.aspx?iditem=%ce%9135%ce%a7.
- Greek Ministry of Health. DRG code: ΠΑ46Α. Diagnostic Related Groups 2020 May 1. Available from: http://kenicd.e-healthnet.gr/KEN%CE%91%CE%BD%CE%B1%CE%BB%CF%85%CF%84%CE%B9%CE%BA%CE%AC.aspx?iditem=%ce%a046%ce%91.
- Greek Ministry of Health. DRG code: Σ22X. Diagnostic Related Groups 2020 May 1. Available from: http://kenicd.e-healthnet.gr/KEN%CE%91%CE%BD%CE%B1%CE%BB%CF%85%CF%84%CE%B9%CE%BA%CE%AC.aspx?iditem=%ce%a322%ce%a7.
- Greek Ministry of Health. DRG code: Π03Μ. Diagnostic Related Groups 2020 May 1. Available from: http://kenicd.e-healthnet.gr/KEN%CE%91%CE%BD%CE%B1%CE%BB%CF%85%CF%84%CE%B9%CE%BA%CE%AC.aspx?iditem=%ce%a003%ce%9c.
- Greek Ministry of Health. DRG code: Π03Χα. Diagnostic Related Groups 2020 May 1. Available from: http://kenicd.e-healthnet.gr/KEN%CE%91%CE%BD%CE%B1%CE%BB%CF%85%CF%84%CE%B9%CE%BA%CE%AC.aspx?iditem=%ce%a003%ce%a7%ce%b1.
- Woods B, Revill P, Sculpher M, et al., Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 19(8): 929–935. 2016.
- Thokala P, Ochalek J, Leech AA, et al. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018 May;36(5):509–522.
- Cameron D, Ubels J. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. 2018;11:1447828.
- Tzanetakos C, Stefanou G, Gourzoulidis G. PNS61 does a standard willingness-to-pay threshold exist in Greece?. Value Health. 2019;22:S772–S773.
- International Monetary Fund. World economic outlook database. October 2019 [ cited 2020 May 16]. Available from: https://www.imf.org/external/pubs/ft/weo/2019/02/weodata/index.aspx
- Zhou K, Zhou J, Zhang M, et al. Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. Clin Transl Oncol. 2020 Mar;22(3):337–343.
- Bullement A, Underhill S, Fougeray R, et al. Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic colorectal cancer in England and Wales. Clin Colorectal Cancer. 2018 Mar;17(1):e143–e151.